Monte Rosa stockholders elect three Class II directors, ratify Deloitte as auditor

Monte Rosa Therapeutics, Inc.

Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D. elected as Class II directors for three-year terms ending 2029.
Schiff received 71.4M votes for, 741K withheld; Manning received 57.0M for, 15.2M withheld.
Ratification of Deloitte & Touche LLP as independent auditor for FY2026 passed with 75.2M for, 58K against, 50K abstain.
No other matters were submitted to or voted on at the June 11, 2026 Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Monte Rosa Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Monte Rosa Therapeutics, Inc. shareholders approved Election of three Class II directors: Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. at the 2026-06-11 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

The stockholders of the Company elected Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successors have been duly elected and qualified or until their earlier resignation or removal.

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-267465

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.